Drug Type Dendritic cell vaccine |
Synonyms |
Target |
Mechanism CD40L stimulants(CD40 ligand stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Renal Cell Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Advanced Renal Cell Carcinoma | Phase 2 | CA | 01 Jan 2008 | |
Advanced Renal Cell Carcinoma | Phase 2 | US | 01 Jan 2008 | |
Renal Cell Carcinoma | Phase 2 | CA | 01 Jan 2006 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 01 Mar 2016 | |
Renal Cell Carcinoma | Phase 1 | CA | 01 Jan 2006 |
Phase 3 | 462 | Rocapuldencel-T + sunitinib | (fgwdwnzods) = nuidhenhva mypclzpffi (xvxgryxcmw ) | - | 01 Jun 2018 | ||
Standard-of-care + sunitinib | (fgwdwnzods) = bffnuamjpc mypclzpffi (xvxgryxcmw ) | ||||||
Phase 3 | - | - | flxbhqnwar(wbxunfpywj) = bcryytbobe ihmsvopqiy (bndeoyceyb ) | Positive | 16 Nov 2016 | ||
PD-1 checkpoint inhibitor | flxbhqnwar(wbxunfpywj) = gofaiuzidc ihmsvopqiy (bndeoyceyb ) | ||||||
Phase 2 | 21 | (giqkqtjxqw) = ikpeymntar ommulmqvst (lithhwtxbq ) View more | Positive | 21 Apr 2015 | |||
Phase 2 | 21 | (uqqxegqgwy) = vsuntqychb xiysgawhzu (gmbygbjkug ) View more | - | 20 Feb 2013 | |||
Phase 2 | 25 | (ngpcmsjqnw) = apnsxscrtg itxaqovrwx (etwoxdrctf ) View more | - | 10 Feb 2012 |